Scilex Holding Co. — Form 8-K Summary
Reporting date: October 17, 2022. The filing was submitted by Vickers Vantage Corp. I, the SPAC pursuing a proposed business combination with Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. The filing primarily reports transaction-related financing, warrant, and lock-up arrangements; it does not provide operating-period financial statements.
Key Transaction and Financial Matters
- Debt contribution: Vickers and its sponsors entered into a Debt Contribution Agreement. The sponsors agreed to contribute certain outstanding loans owed by Vickers in exchange for common shares issued immediately before completion of the business combination, after domestication.
- Contribution share formula: The number of shares will equal the contributed Company Obligations divided by $10.00. The filing does not state the aggregate dollar amount of the Company Obligations or the resulting number of shares.
- Debt extinguishment: Upon issuance of the Contribution Shares, the contributed sponsor obligations will be extinguished in full.
- Funding commitment: Sorrento entered into a Funding Commitment Letter under which it will provide one or more loans to Vickers upon written request, to the extent necessary to satisfy the $5,000,001 net tangible asset closing condition.
- Warrant transfer: Vickers, the sponsors, Sorrento, and Maxim Group LLC entered into a Warrant Transfer Agreement. Certain private placement warrants held by the sponsors may be transferred to Sorrento if shareholder redemptions exceed specified thresholds. The filing does not state those thresholds or the number of warrants subject to transfer.
- Public float: A Letter Agreement provides for the release of sponsor-held shares from lock-up restrictions only as needed to help satisfy Nasdaq’s minimum public-float requirement, capped at 1,500,000 shares.
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity
The filing does not provide revenue, net income, cash flow, operating margins, balance-sheet totals, debt balances, cash balances, or liquidity ratios for Scilex or Vickers. It identifies potential financing support from Sorrento but does not state the amount of committed funding. The proposed merger agreement does not require a minimum level of cash in Vickers’ trust account at closing.
Material Changes Versus the Prior Comparable Period
No comparable-period operating or financial data is presented. Relative to previously disclosed merger arrangements, the filing adds the sponsor debt contribution, Sorrento funding commitment, warrant transfer provisions, and limited sponsor lock-up release mechanism.
Outlook, Risks, and Unusual Items
- Completion of the merger remains subject to shareholder approvals and other closing conditions, including the net tangible asset condition and Nasdaq listing requirements.
- Cash available at closing remains uncertain because of potential shareholder redemptions and the resulting amount remaining in Vickers’ trust account.
- The filing highlights risks related to insufficient transaction proceeds to support Scilex’s short-term operations and research and development, because no minimum trust-account funding level is required for closing.
- Other disclosed risks include merger termination, transaction costs, litigation, regulatory changes, competition, customer retention, employee retention, growth execution, COVID-19 effects, and uncertainty regarding the duration of available funding.
- The Contribution Shares will be issued in an unregistered transaction under Section 4(a)(2) and Rule 506 of Regulation D. They will be subject to resale restrictions except as permitted by registration or an applicable exemption, with contemplated registration rights under a future amended registration rights agreement.
Investor Verification Checklist
- Verify the dollar amount of sponsor obligations being contributed and the resulting number of Contribution Shares.
- Review the full Funding Commitment Letter, including the maximum loan amount, terms, maturity, and conditions to funding.
- Review the Warrant Transfer Agreement for redemption thresholds and the number and terms of warrants potentially transferred to Sorrento.
- Assess the expected trust-account balance after redemptions and the amount of cash available to Scilex at closing.
- Confirm satisfaction of the $5,000,001 net tangible asset condition and Nasdaq’s minimum public-float and listing requirements.
- Review subsequent filings for merger approval, closing status, capitalization changes, financing terms, and any amendments to the transaction agreements.